ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
Healthcare
$11.08 -0.14%
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
52W Low $6.27High $27.40
Volume 0.13M
Average 0.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$28.12M
FY 2025 · Annual
Investing Cash Flow
-$702.00
FY 2025 · Annual
Financing Cash Flow
$20.94M
FY 2025 · Annual
-24.9% YoYCash Flow Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (9.4M) | (24.27M) | (13.21M) | 2.78M | (39.72M) |
| Depreciation & Amortization | 46.46K | 15.07K | 21.16K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 655.2K | 271.54K | 825.81K | 857.63K |
| Change in Working Capital | (1.59M) | 7.26M | 2.94M | (11.73M) | 10.75M |
| Accounts Receivables | (17.57K) | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (32.09K) | 3.6M | 4.96M | (6.11M) | 805.95K |
| Other Working Capital | (1.54M) | 3.66M | (2.02M) | (5.62M) | 9.94M |
| Other Non-Cash Items | 1.5M | (6.55M) | (868.56K) | (19.06M) | (5.59K) |
| Operating Cash Flow | (9.44M) | (22.89M) | (10.84M) | (27.18M) | (28.12M) |
| Capital Expenditures | (6.12K) | (2.66K) | 0 | 0 | 0 |
| Acquisitions (Net) | 99.7K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (33.56K) | (41.67K) | (32.36K) | (33.05K) | (33.75K) |
| Sales of Investments | 35.92K | 41.67K | 31.01K | 32.36K | 33.05K |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 95.93K | (2.66K) | (1.35K) | (693) | (702) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.63M | 6.68M | 17.75M | 27.85M | 20.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 2.04M | 3.6K | 28.04K | 0 |
| Financing Cash Flow | 25.63M | 8.73M | 17.75M | 27.88M | 20.94M |
| Effect of Forex Changes | (114.46K) | (707.96K) | (181.43K) | 0 | 0 |
| Net Change in Cash | 16.17M | (14.87M) | 6.72M | 693.02K | (7.17M) |
| Free Cash Flow | (9.45M) | (22.89M) | (10.84M) | (27.18M) | (28.12M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.7M
+ D&A$0
+ Stock-Based Comp$857.6K
+ Deferred Tax$0
+ Working Capital$10.7M
- Other Non-Cash-$5.6K
= Operating Cash Flow-$28.1M
- Capex$0
= Free Cash Flow-$28.1M
Analysis
FY2025 free cash flow is -$28.1M. FCF conversion is 70.8% of net income. Operating cash flow was -$28.1M, with capex of $0. The largest bridge item is Working Capital at $10.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
Does PMN generate free cash flow?
ProMIS Neurosciences, Inc. (PMN) generated -$28.12M of free cash flow in fiscal 2025.
How much operating cash flow does PMN produce?
Operating cash flow was -$28.12M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.